Tirz - Research Peptide

Tirz is a synthetic dual GIP and GLP-1 receptor agonist peptide, representing the second generation of incretin-based research compounds. It is one of the most extensively studied dual receptor agonists in modern pharmacology, with a substantial body of clinical and preclinical literature examining its role in metabolic regulation, insulin sensitivity, and energy homeostasis.

Compound Details

• Molecular Weight: 4813.5 g/mol

• CAS Number: 2023788-19-2

• Purity: >99% (HPLC verified)

• Form: Lyophilised powder

• Available sizes: 5mg, 10mg, 15mg, 20mg, 30mg

Research Background

Academic and clinical studies have investigated tirz involvement in dual GIP and GLP-1 receptor activation, pancreatic beta cell function models, and adipose tissue metabolism. It has also been studied extensively in the context of insulin sensitivity modelling, hepatic lipid regulation, and cardiovascular risk pathway research. As a dual receptor agonist, tirz has been distinguished in research from single receptor GLP-1 compounds by its simultaneous action across two incretin pathways, with multiple large-scale clinical trials examining its metabolic applications. All preclinical research has been conducted in controlled in vitro and animal model settings.

Storage & Handling

Once reconstituted, store at 4°C. For laboratory research use only.

Quality Assurance

Every batch of Tirz supplied by Biomaxx is independently third-party tested and HPLC verified to confirm >99% purity. A Certificate of Analysis (CoA) is available upon request.

For research purposes only. Not for human consumption. Must be handled by qualified researchers in a controlled laboratory environment.